Transgene Biotek Stock Performance
|
|
|
Transgene Biotek Company background
Founded in: 1990
Managing director: K Koteswara Rao
Founded in March, 1990 by Dr. Koteswara Rao, Transgene Biotek Ltd was one of the first Biotechnology companies in India. Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc. The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune.Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immunodiagnostic reagents for qualitative and quantitative estimation of biochemical parameters and diagnosis of diseases respectively.Transgene Bioteks products are exported to Africa, Russia, China, Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility costing Rs. 30 crore at the Anrich Industrial Area, Bollaram. TBL is working of four new plants comprising of Oral deliver of proteins and peptides DNA vaccines fusion proteins and bio therapeutics. The new project is funded through preferential offer to Batterymarch Financial Management USA and Other Financial Institutions (FIs).The Company absorbed the transfer of technology from RBB Inc, USA for the manufacture and marketing of Erythropoietin during year 2003. The Scheme of Arrangement for Amalgamation of M/S Saket Biotechnologies Private Limited (SBPL) with the Company was implemented and made effective on 7th February, 2005. In terms of the said Scheme of Amalgamation, 60,60,000 Equity Shares were allotted to the Sharesholders of M/S Saket Biotechnologies Private limited on 27 April 2005.In 201213, the Company started the commercial production of Omega3 DHA (Docosahexaenoic Acid) . It formulated the molecule belonging to a very large global pharma company for undergoing studies at its own chosen facilities in USA during year 202021. Transgene has been developing novel oral and nasal formulations for the delivery of various protein and peptidebased biologicals through oral and intranasal routes. Transgene is focused on developing novel therapies in the areas of Oncology, AutoImmune diseases and new drug delivery technologies, that have the potential to substantially improve the quality of life of patients in areas of unmet medical need.
Transgene Biotek Financial Highlights
For the full year FY2025–2026, revenue
reached ₹1.04 crore and profit touched at
₹-0.68 crore.
Transgene Biotek Share Price Today
As of 28 Nov 2025, Transgene Biotek share price is ₹3.7. The stock opened at ₹3.6 and had closed at ₹3.6 the previous day. During today’s trading session, Transgene Biotek share price moved between ₹3.56 and ₹3.73, with an average price for the day of ₹3.65. Over the last 52 weeks, the stock has recorded a low of ₹3.21 and a high of ₹8.00. In terms of performance, Transgene Biotek share price has declined by 12.6% over the past six months and has declined by 0% over the last year.
Transgene Biotek Fundamental
Market Cap (in crs)
27.73
Face Value
10
Turnover (in lacs)
1.19
Key Metrics
Qtr Change %
54.25% Fall from 52W High
-6.9
Dividend yield 1yr %
0
Transgene Biotek Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Transgene Biotek Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
0.05 Cr | 0.05 Cr | 0.08 Cr | 0.08 Cr | 0.06 Cr |
Transgene Biotek Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
1.04 Cr | 0.42 Cr | 0.23 Cr | 0.3 Cr | 0.44 Cr | 0.18 Cr |
Transgene Biotek Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
-0.39 Cr | -0.43 Cr | -0.71 Cr | -0.09 Cr | -0.07 Cr |
Transgene Biotek Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
-0.68 Cr | -0.66 Cr | -6.01 Cr | -10.4 Cr | -10.43 Cr | -10.96 Cr |
Transgene Biotek Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
3.66
Current Price
Day EMA5
3.60
Day EMA10
3.70
Day EMA12
3.70
Day EMA20
3.70
Day EMA26
3.80
Day EMA50
3.90
Day EMA100
4.10
Day EMA200
4.50
Day SMA5
3.70
Day SMA10
3.70
Day SMA20
3.70
Day SMA30
3.90
Day SMA50
4.00
Day SMA100
4.20
Day SMA150
4.20
Day SMA200
4.10
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 32587 Rs | 32613 Rs |
Week Rs | 23540 Rs | 27180 Rs |
Month Rs | 46744 Rs | 60159 Rs |
Resistance & Support
3.65
Pivot
Resistance
First Resistance
3.74
Second Resistance
3.82
Third Resistance
3.91
Support
First Support
3.57
Second support
3.48
Third Support
3.40
Relative Strength Index
45.85
Money Flow Index
44.71
MACD
-0.10
MACD Signal
-0.10
Average True Range
0.36
Average Directional Index
32.29
Rate of Change (21)
-12.44
Rate of Change (125)
-14.88
Transgene Biotek Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
63.61 | 32.06 | 54.35 | 112.45 | 57.45 | 7.70% | -7.73% | -13.82% | -33.81% | -37.14% | 0.00% | 0.00 | 53.14 | 2.15 | |
3.81 | 20.58 | 3.4 | 7.6 | 3.85 | -1.30% | -12.81% | -16.08% | -43.97% | -70.85% | 0.00% | 0.00 | 88.13 | 2.52 | |
44.01 | 43.37 | 32.1 | 46.92 | - | -0.05% | 9.78% | 11.45% | 3.55% | 64.83% | 0.00% | 40.61 | 88.13 | -73.69 | |
22.57 | 16.05 | 19.08 | 50.33 | 23.75 | -9.72% | -9.10% | -8.99% | -53.92% | -69.44% | 0.00% | 0.00 | 88.13 | 0.76 | |
16.00 | 39.60 | 14.5 | 32.89 | 15.79 | -5.88% | 2.43% | -24.49% | -43.46% | -56.52% | 0.00% | 28.07 | 88.13 | 0.36 | |
11.26 | 11.64 | 11.16 | 21.45 | 11.66 | -7.48% | -11.96% | -30.84% | -41.23% | -42.26% | 0.00% | 112.60 | 88.13 | 0.59 |
Transgene Biotek Share Price FAQs
How to buy Transgene Biotek shares?
You can easily buy Transgene Biotek shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Transgene Biotek ?
The 52-week high and low of Transgene Biotek share price is ₹8 and ₹3.21 as of 27/11/2025.
Please be aware that Transgene Biotek stock prices are subject to continuous fluctuations due to various factors.
Invest in Transgene Biotek